v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $ (1,779,217) $ (827,199) $ (2,160,998) $ (48,319,475)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization expense 1,441 3,155 711,929
Amortization of contract asset 129,072 129,072
Stock compensation expense 58,908 750,027 1,523,489 1,575,952
Loss on ELOC share settlements 27,880    
Gain on extinguishment of forward purchase derivative     (3,336,213)
Amortization of share-based consulting services 52,750 59,857
Net deferred indemnified loan origination fees     (63,275)
Discount on common stock sold pursuant to the ELOC     76,553
Other non-cash issuance costs related to the ELOC     800,000
Shares issued in settlement of a legal dispute     200,000
Non-cash interest on issuance of convertible notes     137,500
Amortization of marketing costs settled with common stock 50,000    
Lease expense (4,757) 892 (7,981) 23,181
Credit benefit (316,576) (177,917) (1,393,131)
Impairment of goodwill     6,058,000
Impairment of long-lived intangible assets     3,090,881
Deferred tax expense, net     43,859,686
Marketing expense settled via Common Stock     100,000
Change in fair value of warrant liabilities (16,599) (1,116,082) (1,320,871) (2,803,638)
Change in the fair value of deferred consideration (161,000) (79,475) (361,449)
Changes in operating assets and liabilities:        
Accounts receivable – trade 1,109 43,813 103,233 (12,734)
Accounts receivable – related party 284,583 333,947 (41,460) 1,127,297
Prepaid expenses 158,897 101,005 561,913 86,901
Other current liabilities (110,689) 17,016 (48,960) 527
Accrued interest receivable 13,418 16,319 (2,542)
Other current assets     4,057 (2,968,061)
Accounts payable 683,824 126,924 49,105 (76,672)
Accounts payable – related party (9,614) 82,220 95,757 (501,709)
Accrued expenses (238,331) (535,902) 9,085 292,396
Contract liabilities 103 (19,230)    
Other assets (236)    
Deferred revenue     (12,920) 6,413
Net cash used in operating activities (1,078,657) (1,140,730) (3,417,700) 430,477
CASH FLOWS FROM INVESTING ACTIVITIES:        
Proceeds from sale of preferred securities     50,000
Net proceeds from loan repayment 3,245 392,186 12,394
Proceeds from redemption of investment 25,017    
Net cash provided by investing activities 25,017 3,245 442,186 12,394
CASH FLOWS FROM FINANCING ACTIVITIES:        
Tax withholding payments on vesting of restricted stock units     (12,771)
Proceeds from convertible debt     550,000
Redemption of Series B Convertible Preferred Stock     (292,800)
Gross proceeds from issuance of Series B Convertible Preferred Stock and Series B Warrants     6,130,000
Offering cost     (351,646)
Proceeds from the sale of Class A Common Stock 172,070 1,778,987
Repayment of financed insurance contract     (116,098)
Repayment of senior secured promissory note (255,765) (255,765) (3,006,993)
Net cash provided by (used in) financing activities 172,070 (255,765) 7,429,907 (3,006,993)
Net decrease in cash and cash equivalents (881,570) (1,393,250) 4,454,393 (2,564,122)
Cash and cash equivalents – beginning of period 6,779,040 2,324,647 2,324,647 4,888,769
Cash and cash equivalents – end of period 5,897,470 931,397 6,779,040 2,324,647
Supplemental Disclosure of Non-Cash Investing and Financing Activities        
Interest paid 4,580 113,561 388,457 416,852
Non cash transactions:        
Reclassification of forward purchase receivable 4,584,221 (4,584,221)
Accrued redemption payable to Series B holders 43,018    
Marketing expense settled by the issuance of Common Stock     50,000
Investment in preferred securities   1,500,000
Prepaid consulting expense from the issuance of the Series B Convertible Preferred Stock and Series B Warrants     371,307
Extinguishment of debt for issuance of Series B Convertible Preferred Stock and Series B Warrants     10,748,408
Exchange of forward purchase derivative liability for the issuance of Series B Convertible Preferred Stock and Series B Warrants     4,000,867
Exchange of convertible notes for Series B Convertible Preferred Stock and Series B warrants     659,997
Financed insurance contract (classified in accrued expense)     395,900
Issuance of stock to Abaca shareholders     258,868
Accrued redemption payable to Series B holders     181,378
Recognition of contract asset with corresponding stand-ready guarantee liability     2,135,000
Recognition of contract asset with corresponding financial indemnification liability     $ 1,091,772